References
- Aletaha D, Neogi T, Silman AJ et al. (2010) 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581.
https://doi.org/10.1002/art.27584 - Balkarli A, Tekintürk S, Kaptanoğlu B et al. (2016) Relationship between plasma levels of homocysteine and pro-inflammatory cytokines in patients with rheumatoid arthritis. J Clin Exp Investig 7:163–167.
https://doi.org/10.5799/ahinjs.01.2016.02.0590 - Beckman JD, DaSilva A, Aronovich E et al. (2023) JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte–endothelial proadhesive interactions. J Thromb Haemost 21:1366–1380.
https://doi.org/10.1016/j.jtha.2023.01.027 - Belch JJ, McArdle B, Madhok R et al. (1984) Decreased plasma fibrinolysis in patients with rheumatoid arthritis. Ann Rheum Dis 43:774–777.
https://doi.org/10.1136/ard.43.6.774 - Bezuidenhout JA, Venter C, Roberts TJ et al. (2020) Detection of citrullinated fibrin in plasma clots of rheumatoid arthritis patients and its relation to altered structural clot properties, disease-related inflammation and prothrombotic tendency. Front Immunol 11:577523.
https://doi.org/10.3389/fimmu.2020.577523 - Brown PM, Pratt AG, Isaacs JD (2016) Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 12:731–742.
https://doi.org/10.1038/nrrheum.2016.175 - Chen-Goodspeed A, Dronavalli G, Zhang X et al. (2023) Antithrombin activity is associated with persistent thromboinflammation and mortality in patients with severe COVID-19 illness. Acta Haematol 146:117–124.
https://doi.org/10.1159/000528584 - Ciechomska M, Roszkowski L, Burakowski T et al. (2023) Circulating miRNA-19b as a biomarker of disease progression and treatment response to baricitinib in rheumatoid arthritis patients through miRNA profiling of monocytes. Front Immunol 14:980247.
https://doi.org/10.3389/fimmu.2023.980247 - Di Minno MND, Dentali F, Lupoli R et al. (2014) Mild antithrombin deficiency and risk of recurrent venous thromboembolism: A prospective cohort study. Circulation 129:497–503.
https://doi.org/10.1161/CIRCULATIONAHA.113.003756 - England BR, Roul P, Yang Y et al. (2021) Burden and trajectory of multimorbidity in rheumatoid arthritis: A matched cohort study from 2006 to 2015. Ann Rheum Dis 80:286–292.
https://doi.org/10.1136/annrheumdis-2020-218282 - Feng Y, Kang K, Xue Q et al. (2020) Value of plasma homocysteine to predict stroke, cardiovascular diseases, and new-onset hypertension: A retrospective cohort study. Medicine (Baltimore) 99:e21541.
https://doi.org/10.1097/MD.0000000000021541 - Fransen J, Van Riel PLCM (2009) The disease activity score and the EULAR response criteria. Rheum Dis Clin North Am 35: 745–757.
https://doi.org/10.1016/j.rdc.2009.10.001 - Göbel K, Eichler S, Wiendl H et al. (2018) The coagulation factors fibrinogen, thrombin, and factor XII in inflammatory disorders – A systematic review. Front Immunol 9:1731.
https://doi.org/10.3389/fimmu.2018.01731 - Habib SS, Al-Khlaiwi T, Almushawah A et al. (2023) Homocysteine as a predictor and prognostic marker of atherosclerotic cardiovascular disease: A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 27:8598–8608.
https://doi.org/10.26355/eurrev_202309_33784 - Hansildaar R, Raadsen R, Heslinga M et al. (2023) AB0397 no clinically relevant changes in coagulation activation between patients initiating TNF-blockers versus JAK-inhibitors. Ann Rheum Dis 82(Suppl. 1):1382.
https://doi.org/10.1136/annrheumdis-2023-eular.2199 - Huang S, Cai J, Tian Y (2021) The prognostic value of homocysteine in acute ischemic stroke patients: A Systematic review and meta-analysis. Front Syst Neurosci 14:600582.
https://doi.org/10.3389/fnsys.2020.600582 - Jensen OK, Rasmussen C, Mollerup F et al. (2002) Hyperhomocysteinemia in rheumatoid arthritis: Influence of methotrexate treatment and folic acid supplementation. J Rheumatol 29:1615–1618.
- Jones HW, Bailey R, Zhang Z et al. (1998) Inactivation of antithrombin III in synovial fluid from patients with rheumatoid arthritis. Ann Rheum Dis 57:162–165.
https://doi.org/10.1136/ard.57.3.162 - Katsushima M, Minamino H, Shirakashi M et al. (2023) High plasma homocysteine level is associated with increased prevalence of the non-remission state in rheumatoid arthritis: Findings from the KURAMA cohort. Mod Rheumatol 33:911–917.
https://doi.org/10.1093/mr/roac106 - Kotyla PJ, Engelmann M, Giemza-Stokłosa J et al. (2021) Thromboembolic adverse drug reactions in Janus kinase (JAK) inhibitors: Does the inhibitor specificity play a role? Int J Mol Sci 22:2449.
https://doi.org/10.3390/ijms22052449 - Kotyla PJ, Islam MA, Engelmann M (2020) Clinical aspects of Janus kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. Int J Mol Sci 21:7390.
https://doi.org/10.3390/ijms21197390 - Lethen I, Lechner-Grimm K, Gabel M et al. (2024) Tofacitinib affects M1-like and M2-like polarization and tissue factor expression in macrophages of healthy donors and IBD patients. Inflamm Bowel Dis 30:1151–1163.
https://doi.org/10.1093/ibd/izad290 - McEntegart A, Capell HA, Creran D et al. (2001) Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 40:640–644.
https://doi.org/10.1093/rheumatology/40.6.640 - Meng R, Li ZY, Ji X et al. (2011) Antithrombin III associated with fibrinogen predicts the risk of cerebral ischemic stroke. Clin Neurol Neurosurg 113:380–386.
https://doi.org/10.1016/j.clineuro.2010.12.016 - Molander V, Bower H, Frisell T et al. (2021) Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: A nationwide cohort study from Sweden. Ann Rheum Dis 80:169–175.
https://doi.org/10.1136/annrheumdis-2020-218419 - Ordóñez A, Yélamos J, Pedersen S et al. (2010) Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody. Thromb Haemost 104:1143–1149.
https://doi.org/10.1160/TH10-05-0297 - Peshkova AD, Evdokimova TA, Sibgatullin TB et al. (2020) Accelerated spatial fibrin growth and impaired contraction of blood clots in patients with rheumatoid arthritis. Int J Mol Sci 21:9434.
https://doi.org/10.3390/ijms21249434 - Popescu D, Rezus E, Badescu MC et al. (2023) Cardiovascular risk assessment in rheumatoid arthritis: Accelerated atherosclerosis, new biomarkers, and the effects of biological therapy. Life 13:319.
https://doi.org/10.3390/life13020319 - Ravid JD, Leiva O, Chitalia VC (2022) Janus kinase signaling pathway and its role in COVID-19 inflammatory, vascular, and thrombotic manifestations. Cells 11:306.
https://doi.org/10.3390/cells11020306 - Rho YH, Oeser A, Chung CP et al. (2009) Drugs used in the treatment of rheumatoid arthritis: Relationship between current use and cardiovascular risk factors. Arch Drug Inf 2:34–40.
https://doi.org/10.1111/j.1753-5174.2009.00019.x - Rooney T, Scherzer R, Shigenaga JK et al. (2011) Levels of plasma fibrinogen are elevated in well-controlled rheumatoid arthritis. Rheumatology 50:1458–1465.
https://doi.org/10.1093/rheumatology/ker011 - Seriolo B, Accardo S, Garnero A et al. (1999) Anticardiolipin antibodies, free protein S levels and thrombosis: A survey in a selected population of rheumatoid arthritis patients. Rheumatology 38:675–678.
https://doi.org/10.1093/rheumatology/38.7.675 - Sinkiewicz W, Błażejewski J, Bujak R et al. (2006) Ocena stężenia kompleksów trombina-antytrombina III i aktywności antytrombiny III u pacjentów z ostrym zawałem serca. Folia Cardiol 1:203–210.
- Soós B, Hamar A, Pusztai A et al. (2022) Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: A metabolomic approach. Front Med 9:1011734.
https://doi.org/10.3389/fmed.2022.1011734 - Taylor PC, Chen Y-F, Pope J et al. (2023) Patient disease trajectories in rheumatoid arthritis patients treated with baricitinib 4-mg in four phase 3 clinical studies. Rheumatol Ther 10:463–476.
https://doi.org/10.1007/s40744-022-00529-7 - Thompson SG, Fechtrup C, Squire E et al. (1996) Antithrombin III and fibrinogen as predictors of cardiac events in patients with angina pectoris. Artherioscler Thromb Vasc Biol 16:357–362.
https://doi.org/10.1161/01.ATV.16.3.357 - Tilvawala R, Nguyen SH, Maurais AJ et al. (2018) The rheumatoid arthritis-associated citrullinome. Cell Chem Biol 25:691–704.e6.
https://doi.org/10.1016/j.chembiol.2018.03.002 - Türk SM, Cansu DÜ, Teke HÜ et al. (2018) Can we predict thrombotic tendency in rheumatoid arthritis? A thromboelastographic analysis (with ROTEM). Clin Rheumatol 37:2341–2349.
https://doi.org/10.1007/s10067-018-4134-y - Undas A, Gissel M, Kwasny-Krochin B et al. (2010) Thrombin generation in rheumatoid arthritis: Dependence on plasma factor composition. Thromb Haemost 104:224–230.
https://doi.org/10.1160/TH10-02-0091 - Wallberg-Jonsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 24:445–451.
- Westerlind H, Kastbom A, Rönnelid J et al. (2023) The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis. Rheumatology 62:2106–2112.
https://doi.org/10.1093/rheumatology/keac601 - Xie W, Huang Y, Xiao S et al. (2019) Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: Systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 78:1048–1054.
https://doi.org/10.1136/annrheumdis-2018-214846 - Xu L, Zhang H, Wang Y et al. (2022) FABP4 activates the JAK2/STAT2 pathway via Rap1a in the homocysteine-induced macrophage inflammatory response in ApoE mice atherosclerosis. Lab Invest 102:25–37.
https://doi.org/10.1038/s41374-021-00679-2 - Yang X, Gao F, Liu Y (2015) Association of homocysteine with immunological-inflammatory and metabolic laboratory markers and factors in relation to hyperhomocysteinaemia in rheumatoid arthritis. Clin Exp Rheumatol 33:900–903.